Patent · US Active

Selective cell therapy for the treatment of renal failure

US9534203B2 · kind B2 · utility

5Cited by
65References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 16, 2015
Grant dateJan 3, 2017
Priority date
Expiry dateSep 16, 2035

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2015/1028
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro. The kidney cells may include peritubular interstitial cells of the kidney, and preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells produce EPO in vivo.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.